Repositioning of Memantine as a Potential Novel Therapeutic Agent against Meningitic E. coli–Induced Pathogenicities through Disease-Associated Alpha7 Cholinergic Pathway and RNA Sequencing-Based Transcriptome Analysis of Host Inflammatory Responses
Authors:
Open Access
- 19 May 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (5) , e0121911
Abstract
Neonatal sepsis and meningitis (NSM) remains a leading cause worldwide of mortality and morbidity in newborn infants despite the availability of antibiotics over the last several decades. E. coli is the most common gram-negative pathogen causing NSM. Our previous studies show that α7 nicotinic receptor (α7 nAChR), an essential regulator of inflammation, plays a detrimental role in the host defense against NSM. Despite notable successes, there still exists an unmet need for new effective therapeutic approaches to treat this disease. Using the in vitro/in vivo models of the blood-brain barrier (BBB) and RNA-seq, we undertook a drug repositioning study to identify unknown antimicrobial activities for known drugs. We have demonstrated for the first time that memantine (MEM), a FDA-approved drug for treatment of Alzheimer’s disease, could very efficiently block E. coli-caused bacteremia and meningitis in a mouse model of NSM in a manner dependent on α7 nAChR. MEM was able to synergistically enhance the antibacterial activity of ampicillin in HBMEC infected with E. coli K1 (E44) and in neonatal mice with E44-caused bacteremia and meningitis. Differential gene expression analysis of RNA-Seq data from mouse BMEC infected with E. coli K1 showed that several E44-increased inflammatory factors, including IL33, IL18rap, MMP10 and Irs1, were significantly reduced by MEM compared to the infected cells without drug treatment. MEM could also significantly up-regulate anti-inflammatory factors, including Tnfaip3, CISH, Ptgds and Zfp36. Most interestingly, these factors may positively and negatively contribute to regulation of NF-κB, which is a hallmark feature of bacterial meningitis. Furthermore, we have demonstrated that circulating BMEC (cBMEC) are the potential novel biomarkers for NSM. MEM could significantly reduce E44-increased blood level of cBMEC in mice. Taken together, our data suggest that memantine can efficiently block host inflammatory responses to bacterial infection through modulation of both inflammatory and anti-inflammatory pathways.Keywords
This publication has 53 references indexed in Scilit:
- Circulating Brain Microvascular Endothelial Cells (cBMECs) as Potential Biomarkers of the Blood–Brain Barrier Disorders Caused by Microbial and Non-Microbial FactorsPLOS ONE, 2013
- Associations between Genetic Polymorphisms in IL-33, IL1R1 and Risk for Inflammatory Bowel DiseasePLOS ONE, 2013
- Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitisScientific Reports, 2011
- Differential expression in RNA-seq: A matter of depthGenome Research, 2011
- The clinically available NMDA receptor antagonist, memantine, exhibits relative safety in the developing rat brainInternational Journal of Developmental Neuroscience, 2011
- Risk factors of mortality in septic newborns in neonatal intensive care units (NICUs) in Tbilisi, the Republic of GeorgiaEuropean Journal of Epidemiology, 2009
- Review: Pathophysiology and treatment of bacterial meningitisTherapeutic Advances in Neurological Disorders, 2009
- Lactobacillus rhamnosusGG Suppresses MeningiticE. coliK1 Penetration across Human Intestinal Epithelial Cells In Vitro and Protects Neonatal Rats against Experimental Hematogenous MeningitisInternational Journal of Microbiology, 2008
- Mapping and quantifying mammalian transcriptomes by RNA-SeqNature Methods, 2008
- Focal Point Theory Models for Dissecting Dynamic Duality Problems of Microbial InfectionsBioMed Research International, 2008